Joaquin Rodrigo, General Manager – Sandoz Iberia
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Sandoz was a company that merged with Ciba-Geigy to form Novartis. The name was later reused as the name of Novartis’ generic drug subsidiary.
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable and reliable access to critical and essential…
Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent attraction, and navigating the COVID-19 crisis. The US…
Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz globally as well as its position in the country.…
Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies…
Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration…
Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio…
Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing…
The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics. Could you please…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
Mr. Willis, you have a background as a management consultant in New Zealand and Australia. What was the situation of the generics market when you arrived in the Philippines and…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country,…
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
See our Cookie Privacy Policy Here
